Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events

Clinical Pharmacokinetics

Volumn 39, Issue 6, 2000, Pages 397-412

  Hatanaka, T ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450; DICLOFENAC; FLUINDOSTATIN; GEMFIBROZIL; ITRACONAZOLE; MEVINOLIN; PRAVASTATIN; PROBUCOL; PROPRANOLOL; RIFAMPICIN; SIMVASTATIN; WARFARIN;

ACTIVE TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HUMAN; HYDROPHOBICITY; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; PRIORITY JOURNAL; REVIEW;

EID: 0034495168     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039060-00002     Document Type: Review

References (95)

1. Heterozygous familial hypercholesterolemia and the relationship between plasma lipids, lipoproteinemias, clinical manifestations and ischemic heart disease in men and women
2. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence
3. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia
4. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Lipid lowering, regression, and coronary events - A review of the interdisciplinary council on lipids and cardiovascular risk intervention, Seventh council meeting
7. Regulation of cholesterol metabolism 3
8. A receptor-mediated pathway for cholesterol homeostasis
9. The discovery and development of HMG-CoA reductase inhibitors
10. Discovery, biochemistry and biology of lovastatin
11. 3-Hydroxy-3methylglutaryl-coenzyme A reductase inhibitors 4: Side chain ester derivatives of mevinolin
12. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
13. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
14. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
15. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture
16. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone
17. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
18. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys
19. Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin
20. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of cholesterol synthesis and hypolipidemic effect on various animal species
21. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
22. Pravastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
23. Clinical pharmacokinetics of pravastatin
24. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
25. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
26. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
27. Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine
28. Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus: ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase
29. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
30. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
31. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin
32. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin
33. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
34. Determination of pravastatin sodium and its major metabolite in serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry
35. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
36. Enzyme-linked immunosorbent assay of pravastatin, a HMG-CoA reductase inhibitor, in human plasma
37. Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence determination after immobilized antibody extraction
38. An automated method for the simultaneous detection of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry
39. Concentration of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects
40. Pharmacokinetics of pravastatin in elderly versus young men and women
41. Effect of food on pravastatin pharmacokinetics and pharmacodynamics
42. Steady state serum concentrations of pravastatin and digoxin when given in combination
43. Biotransformation of pravastatin sodium in human
44. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia
45. Phase I study of CS-514, an inhibitor of HMG-CoA reductase II: Pharmacokinetics of CS-514 in healthy volunteers
46. A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers
47. Pravastatin sodium (CS-514): A novel cholesterol-lowering agent which inhibits HMG-CoA reductase
48. Gastrointestinal absorption of pravastatin in healthy subjects
49. The physiological disposition of lovastatin
50. Proton-cotransport of pravastatin across intestinal brush-border membrane
51. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism
52. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types
53. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo
54. Tissue selectivity of HMG-CoA reductase inhibitors
55. Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system
56. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes
57. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier
58. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin: The relationship between inhibition of de novo synthesis and active drug concentrations in liver, spleen and testis in rat
59. Uptake is the ratelimiting step in the overall hepatic elimination of pravastatin at steady-state in rats
60. Primary active transport of organic anions on bile canalicular membrane in humans
61. Excretion of pravastatin, an HMG-CoA reductase inhibitor, in breast milk of lactating women
62. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin
63. Biotransformation of pravastatin sodium (I): Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium
64. Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin
65. Comparison of cytochrome P-450-dependent mechanism and drug interactions of the 3-hydroxy-3-methylglutaryl-Co A reductase inhibitors lovastatin and pravastatin in the liver
66. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6, and CYP3A4) by HMG-CoA reductase inhibitors
67. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment
68. The pharmacokinetics of pravastatin in patients on chronic hemodialysis
69. Interactions with hydroxymethyl-glutaryl-coenzyme A reductase inhibitors
70. Pharmacokinetics of fluvastatin and specific drug interactions
71. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor
72. Effect of an anticholinergic agent on riboflavin absorption in man
73. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
74. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
75. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase inhibitors
76. Clinical experience with lovastatin
77. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin
78. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
79. Influence of cholestyramine on the pharmacokinetics of cerivastatin
80. Adverse reactions and interactions with β-adrenoceptor blocking drugs
81. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
82. The interaction of diltiazem with lovastatin and pravastatin
83. Antipyrine elimination is not affected by chronic administration of pravastatin (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor
84. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
85. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
86. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses
87. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor activity in kidney transplant recipients with and without ciclosporin
88. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
89. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
90. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-) fluvastatin
91. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
92. Pharmacology of competitive inhibitors of HMG-CoA reductase
93. Interspecies scaling in pharmacokinetics
94. Reconstruction of drug dispositions in vivo from in vitro studies based on physiological pharmacokinetic modeling: From low-molecular weight drugs to polypeptide compounds